RxDoctor Payments Data

David Hogarty

Goldsboro, NCNPI 1760447528

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Amgen at 32.9% of the total. Reporting peaked in 2020 at $1,110 and has fallen 98.6% since, to $15 in 2023.

$2,897in general payments, 2019–2025

Across 172 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$954
  • Johnson & Johnson$382
  • AbbVie$323
  • UCB, Inc.$282
  • Actelion Pharmaceuticals US, Inc.$164
  • Lilly USA, LLC$163
  • plus $629 from 14 others

What the payments were for

  • Food & beverage$2,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Where these figures come from

Is this you, or does something look wrong? →